The Risks of Prescription Drugs (A Columbia / SSRC Book (Privatization of Risk))
The Risks of Prescription Drugs (A Columbia / SSRC Book (Privatization of Risk)) is backordered and will ship as soon as it is back in stock.
Couldn't load pickup availability
                    
                      
Genuine Products Guarantee
                      
                    
                  
                  Genuine Products Guarantee
We guarantee 100% genuine products, and if proven otherwise, we will compensate you with 10 times the product's cost.
                    
                      
Delivery and Shipping
                      
                    
                  
                  Delivery and Shipping
Products are generally ready for dispatch within 1 day and typically reach you in 3 to 5 days.
Author: Light, Donald
Brand: Columbia University Press
Binding: paperback
Number Of Pages: 184
Release Date: 14-10-2010
Details: Few people realize that prescription drugs have become a leading cause of death, disease, and disability. Adverse reactions to widely used drugs, such as psychotropics and birth control pills, as well as biologicals, result in FDA warnings against adverse reactions. The Risks of Prescription Drugs describes how most drugs approved by the FDA are under-tested for adverse drug reactions, yet offer few new benefits. Drugs cause more than 2.2 million hospitalizations and 110,000 hospital-based deaths a year. Serious drug reactions at home or in nursing homes would significantly raise the total. Women, older people, and people with disabilities are least used in clinical trials and most affected. Health policy experts Donald Light, Howard Brody, Peter Conrad, Allan Horwitz, and Cheryl Stults describe how current regulations reward drug companies to expand clinical risks and create new diseases so millions of patients are exposed to unnecessary risks, especially women and the elderly. They reward developing marginally better drugs rather than discovering breakthrough, life-saving drugs. The Risks of Prescription Drugs tackles critical questions about the pharmaceutical industry and the privatization of risk. To what extent does the FDA protect the public from serious side effects and disasters? What is the effect of giving the private sector and markets a greater role and reducing public oversight? This volume considers whether current rules and incentives put patients' health at greater risk, the effect of the expansion of disease categories, the industry's justification of high U.S. prices, and the underlying shifts in the burden of risk borne by individuals in the world of pharmaceuticals. Chapters cover risks of statins for high cholesterol, SSRI drugs for depression and anxiety, and hormone replacement therapy for menopause. A final chapter outlines six changes to make drugs safer and more effective. Suitable for courses on health and aging, gender, disability, and m
EAN: 9780231146937
Package Dimensions: 8.0 x 5.4 x 0.6 inches
Languages: English
 
            
 
       
         

